IQVIA Holdings Inc. $IQV Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,265 shares of the medical research company’s stock after selling 685 shares during the quarter. Retirement Systems of Alabama’s holdings in IQVIA were worth $5,557,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Brighton Jones LLC boosted its stake in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after acquiring an additional 2,537 shares in the last quarter. Private Trust Co. NA raised its holdings in IQVIA by 22.4% during the first quarter. Private Trust Co. NA now owns 536 shares of the medical research company’s stock worth $94,000 after purchasing an additional 98 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in IQVIA by 201.6% during the first quarter. Teacher Retirement System of Texas now owns 32,432 shares of the medical research company’s stock worth $5,718,000 after purchasing an additional 21,679 shares during the last quarter. Mutual Advisors LLC raised its holdings in IQVIA by 85.1% during the first quarter. Mutual Advisors LLC now owns 3,126 shares of the medical research company’s stock worth $551,000 after purchasing an additional 1,437 shares during the last quarter. Finally, Concurrent Investment Advisors LLC raised its holdings in IQVIA by 39.3% during the first quarter. Concurrent Investment Advisors LLC now owns 7,680 shares of the medical research company’s stock worth $1,354,000 after purchasing an additional 2,166 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IQV. Mizuho lifted their price objective on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. HSBC raised IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. JPMorgan Chase & Co. upped their target price on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Stifel Nicolaus upped their target price on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Redburn Partners set a $214.00 target price on IQVIA in a research note on Wednesday, September 3rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $239.94.

IQVIA Trading Down 1.2%

Shares of IQVIA stock opened at $213.82 on Tuesday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $225.91. The firm has a market cap of $36.41 billion, a PE ratio of 29.33, a P/E/G ratio of 2.42 and a beta of 1.34. The business’s fifty day moving average is $197.64 and its two-hundred day moving average is $174.62. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.60% of the stock is currently owned by insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.